Corporate ActionAug 3, 2026, 06:13 AM
BlossomHill Therapeutics to IPO 7.81M Shares at $15-17 per Share
AI Summary
BlossomHill Therapeutics, Inc. filed an S-1/A for its initial public offering of 7,812,500 common shares, priced between $15.00 and $17.00 per share. The offering is expected to generate approximately $111.7 million in net proceeds, which will fund the clinical development of its lead oncology programs, BH-30643, BH-30236, and preclinical BH-501284. The company is a clinical-stage biopharmaceutical firm focused on small molecule medicines for cancer, with plans to list on Nasdaq under 'BLSM'.
Key Highlights
- Initial public offering of 7,812,500 common shares.
- Expected IPO price range of $15.00 to $17.00 per share.
- Estimated net proceeds of approximately $111.7 million.
- Underwriters' option to purchase up to 1,171,875 additional shares.
- Proceeds to fund clinical development of BH-30643, BH-30236, and BH-501284.
- BH-30643: Plans FDA meeting in Q4 2026 for C797S-positive EGFR-mutant NSCLC.
- BH-30236: Updated Phase 1 data expected in H1 2027 for R/R AML and HR-MDS.
- BH-501284: IND submission planned for Q1 2027 for pan-KRAS inhibitor.
Price Impact
More from BLSM